DePuy Synthes acquires OrthoSpin

The Johnson & Johnson Medical Devices Companies announced DePuy Synthes acquired the Israeli company, OrthoSpin, Ltd. OrthoSpin developed and manufactures an automated strut system used in conjunction with DePuy Synthes MAXFRAME Multi-Axial Correction System, an external ring fixation system. This acquisition is Johnson & Johnson’s continued commitment to advancing innovation in the medtech space.

Ring fixation systems are a common treatment for correcting complex bone deformities, bone lengthening, setting complex fractures, and addressing issues such as nonunion. Currently, treatment necessitates manual strut adjustments by patients and caregivers daily. OrthoSpin’s strut adjustments are automated and may enhance the patient experience, potentially reducing the risk of negative clinical outcomes caused by unintended strut adjustment errors.

Deformity correction with ring fixation plays an important role in orthopedics. DePuy Synthes has been committed to this area with the introduction of the MAXFRAME System in 2017, and with the launch of new frame innovations and planned next generation software. With the addition of the OrthoSpin technology, DePuy Synthes is better positioned to serve healthcare professionals and patients who benefit from these critical advancements during the complex post-surgery recovery period. 

“DePuy Synthes is deeply committed to patients who are in need of deformity correction surgery,” says Oray Boston, Worldwide President, DePuy Synthes Trauma, Extremities, Craniomaxillofacial and Animal Health. “The acquisition of OrthoSpin clearly demonstrates our strong desire to help these patients navigate their recovery with more confidence and less uncertainty with their strut adjustments. It also demonstrates our commitment to bringing transformative medtech advancements to the industry through the application of automated technology that addresses a wide range of orthopedic challenges.”

Johnson & Johnson Innovation – JJDC, Inc. led the Series A financing of OrthoSpin in July 2018 and led the Series B financing in March 2020. Earlier this year, OrthoSpin received 510(k) clearance from the U.S. Food and Drug Administration for its second generation, automated, digitally enabled external fixation system for orthopedic treatments, the OrthoSpin G2 System, which is also licensed as a medical device (AMAR) in Israel.

Since its initial release, the OrthoSpin system has been used in numerous surgical procedures with positive feedback from surgeons and patients. Now that the acquisition is complete, DePuy Synthes will integrate the company and develop a robust supply chain before making the product widely available soon.